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A B S T R A C T
The aim of this study was to investigate statin prescription by family doctors (GP) in primary (PP) and secondary
(SP) prevention of cardiovascular diseases (CVDs). Patients’ socio-demographic data, total cholesterol (TC) and LDL-
-cholesterol (LDL-C) thresholds for statin prescription, indications, data on GP and practices were registred. Statins
were prescribed in 11.2% enlisted patients (64.11% PP, 35.88% SP), mostly aged 70+. In PP, thresholds were TC 6.2±1.09
mmol/L, LDL-C 3.6 mmol/L, in SP 5.4±1.26 mmol/L, 2,7mmol/L, respectively. Most frequently prescribed statin in PP
was 10 mg atorvastatin (49.28%), in SP it was 20 mg simvastatin (48.36%). Participating GPs were women, aged
39±5.49, working for 13±6 years, the average number of enlisted patients per GP 1562±299. There was statisticaly signif-
icant difference in statin prescription in PP (c2=752.9; p<0.001) and SP (c2=64; p<0.001). Statin prescription in PP is
due to pharmaceutical marketing and lack of independent continuing medical education. The fact that statins are most
frequently prescribed in patients aged 70+ (35.28% in PP, 49.35% SP) reveals lack of preventive proactive CVDs ap-
proach in younger age groups, which is concerning.
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Introduction
Cardiovascular diseases (CVDs) are responsible for
53.6% of all deaths registered annually in Croatia, and
therefore represent the leading cause of death1. One of
the key risk factors in developing atherosclerosis is hy-
percholesterolemia, which makes its control and treat-
ment crucial for the primary (PP) and secondary preven-
tion (SP) of CVDs. Statins are efficient in treating hyper-
lipidemia and reducing the risk of adverse cardiovascular
(CV) events both in PP and SP2. The inhibition of HMG-
-CoA reductase (crucial in biosynthesis of the endogen
cholesterol) decreases concentration of total cholesterol
(20%), LDL-cholesterol (28%) and triglycerides (13%),
while HDL-cholesterol level increases (5%)3. By prevent-
ing LDL-cholesterol oxidation, and its macrophage accu-
mulation4, as well as inhibiting smooth muscle cell proli-
feration5, these drugs exhibit an anti-atherogenic effect.
The landmark study demonstrating the importance of
statin use in secondary CHD prevention is the Scandina-
vian Simvastatin Survival Study (4S), carried out in 4444
CHD patients for 5.4 years. Statin use resulted in a
35%-decrease in LDL-cholesterol, a 10%-decrease in tri-
glyceride concentrations, and an 8%-rise in HDL-choles-
terol concentrations, leading to 42%-decrease in mortal-
ity caused by CHD, and a 30%-decrease in all-cause
mortality. These results were even more favourable for
diabetics: 43%-decrease in CVD caused mortality, and
46% in all-cause mortality 46%6. Similar results were
shown in SP after myocardial infarction (CARE and
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LIPID studies) with pravastatin7,8. The effects of statins
in reducing both CVD and all-cause mortality are signifi-
cant in primary CHD prevention, as demonstrated in the
WOSCOPS study with pravastatin and the AFCAPS/
TexCAPS study with lovastatin9,10.
The Heart Protection Study (HPS) demonstrated be-
nefits of simvastatin in SP for population with increased
risk of developing the disease, as well as benefits in those
aged 65+11. EUROASPIRE study, carried out in 9 Euro-
pean countries, showed that in period 1991-1995, hypo-
lipemics were administered to only 32% of the discharged
CHD patients, mostly in inadequately low doses12. The
study was pursued in 15 European countries under the
name EUROASPIRE 2 (1999–2000). It showed increased
percentage of CHD patients receiving hypolipemics up to
43%, but the cholesterol level was unsatisfactory after
1.4 years >5 mmol/L13. According to Reiner14, only 8.83%
of Croatian patients indicated for statin use are pre-
scribed statins and are usually subdosed, so they do not
lower total cholesterol concentration and CVD risk level.
Prospective meta-analysis of the data pooled from 14
randomised statin studies, including 90.056 persons in
total, demonstrated decrease in the incidence of coronary
events, strokes and need for revascularisation in referent
five-year period by one-fifth per mmol/L of LDL-choles-
terol concentration, independently of the initial lipid sta-
tus and other subjects’ features. The same study re-
vealed the increase in therapeutic benefits over the years
of permanent statin use15.
European statin prescription trends, observed in
1997–2003 period, showed significant increase in 13 Eu-
ropean countries, Ireland and Norway taking the lead16.
Based on Croatian Institute for Health Insurance
(CIHI) data for year 2003, simvastatin occupied the six-
teenth position on top 20 list of most commonly pre-
scribed drugs in the Republic of Croatia17. According to
Croatian Agency for Medical Products and Medical De-
vices data for year 2004, simvastatin held the first, and
atorvastatin the eleventh position on the list of the most
frequently sold drugs based on financial indicators, while
on the list of the ten most often used prescription drugs,
simvastatin held the sixth position, and atorvastatin was
not among the top-ten18. The data issued by the same
Agency for year 2005, demonstrated that simvastatin
kept the leading position on the most frequently sold
drugs list based on financial indicators, while atorva-
statin appeared at the fifth position. In the list of the
most frequently used prescription drugs per 1000 in-
sured people simvastatin occupied the fifth, and ator-
vastatin the tenth position19.
According to the CIHI guidelines, the statins may be
prescribed to PP patients whose total serum cholesterol
levels, after 3-month-lasting hypolipemic diet, are still
>7 mmol/L, based on the results of two independent
measurements carried out in a 3-month interval, and the
statin therapy can be initiated with PP patients under
the age of 70. According to the same guidelines, in SP
these drugs are to be prescribed to the patients who suf-
fered myocardial infarction, ischemic stroke (CVI), tran-
sitory ischemic attack (TIA) or have carotid artery pla-
que documented by ultrasound, or with peripheral artery
occlusive disease, coronary disease documented by coro-
narography or ergometry, as well as to diabetics having a
total serum cholesterol level >5 mmol/L20.
Management of patients at CV risk, or those with al-
ready diagnosed CV diseases, represents major segment
in everyday work of a GP. It includes both non-pharmaco-
logical intervention targeted at potential patient (i.e.
counselling on lifestyle changes in terms of an appropri-
ate diet, physical activity, and smoking cessation), and
pharmacological intervention when indicated (treating
arterial hypertension, diabetes and hyperlipedemia). Sta-
tin prescription practices by GP have rarely been the
subject of investigation and consideration of domestic
authors. Our study aims at answering he question: In
what manner, and to whom, does a GP prescribe statins
in primary and secondary CV prevention? We decided to
investigate the following:
• What patterns of statin prescription do GPs exercise in
primary and secondary CV prevention; are there any differ-
ences in statin prescription between PP and SP and if
so, what is the nature of these differences? (main goal)
• Do GPs follow statin prescription guidelines recom-




Study sample was constituted of 7 GPs just having
started their residency in family medicine, providing
healthcare services for the average of 1 600 insured pa-
tients and have electronic medical records. They per-
formed AUDIT analysis of their statin prescription in
primary and secondary prevention (four of practices are
in Zagreb and one in Sunja, Murter and Umag, Croatia).
They registered sociodemographic data [age and age gro-
ups (<40, 40–49, 50–59, 60–69, 70 years), gender], total
and LDL-cholesterol levels at which statins were initially
prescribed, type and dose of prescribed statin, as well as
the reason for prescribing it (PP-»healthy« asymptomatic
individuals at risk for CVD i.e. »pre-event« preventive ac-
tion, or SP-individuals with established CVD or diabetes,
i.e. »re-event« prevention). Indications for SP were noted
(documented coronary heart disease, transitory ischemic
attack, stroke, diabetes, peripheral artery occlusive dis-
ease). Data on the participating GP (age, gender, years of
service, residency) and their practices (number of en-
listed patients, age groups, average number of daily visits
per GP) were collected, too.
Statistics
Data analysis was performed using descriptive statis-
tical methods. The c2-test was used to determine stati-
sticaly significant differences in statin prescription in
primary and secondary prevention as well as the signifi-
cance of different dosing of prescribed statins in PP or
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SP. Student t-test and Mann-Whitney U-test were used to
determine differences between total and LDL-cholesterol
threshold concentrations for statin prescription in PP
compared to SP. Results were interpreted according to
95%-significance level (p<0.05). Data were processed by
using Statistica 6.0 software package, StatSoft Inc, 1984-
–2001, Tulsa, USA.
Results
Out of 10 939 beneficiares of 7 GP's practices, 1282
(11.72%) were prescribed statins. In the age group 40+
(N=7 139), statins were administered to 1281 (17.80%)
patients. Within primary prevention 822 (64.11%) sub-
jects received statins, out of which 71.17% were women
and 28.83% men. The average age of examinees was
62.9±12.45 years. Statins were most frequently prescri-
bed to patients aged 70+ and almost equally frequent to
patients aged 50–59, and 60–69, but rarely in patients
aged 40–49 or under (Table 1). The most frequently pre-
scribed statin in primary prevention was atorvastatin
(49.28%), followed by simvastatin (45.19%). The most
commonly prescribed statin dose was 10 mg (54.38%),
then 20 mg (45.19%), while 40 mg (3.68%) and 80 mg
(1.58%) doses were only seldom prescribed. The average
total cholesterol level at which statin was initially pre-
scribed was 6.2±1.09 mmol/L, median LDL-C 3.6 (0.4–6.4)
mmol/L. In secondary prevention statins were received
by 460 (35.88%) subjects, out of which 61.74% were
women and 38.26% men. The average age of examinees
was 68.3±9.57 years. Statins were most frequently pre-
scribed in 70+ age group, followed by 60–69 and 50–59 to
40–49 or under (Table 1). The most frequently prescribed
was simvastatin (48.36%), followed by atorvastatin
(46.62%). The most frequent dose prescribed in second-
ary prevention was 20 mg (55.89%), 10 mg (33.70%), 40
mg (7.30%) and 80 mg statin a day (3.08%). There was no
statistically significant difference in type of prescribed
statin in primary and secondary prevention (c2=1.15,
p=0.765). However, c2-test demonstrated significant dif-
ference (c2=38.3; p<0.001) between statin doses pre-
scribed in primary and secondary prevention; 40 and 80
mg statin doses were more frequently prescribed in the
latter.
The average total cholesterol level threshold at which
statin was prescribed in secondary prevention was 5.4±1.26
mmol/L, median LDL-C of 2.7 (0.4–5.6) mmol/L.
Student t-test revealed significant difference (t=10.88;
p<0.001) between total cholesterol levels as indications
for statin treatment in PP and SP (the latter being statis-
tically significantly lower). The same goes for LDL-C
concentrations, as revealed by Mann-Whitney U- test
(Z=4.64; p<0.001).
Out of 1 281 statin receiving examinees, 236 (18.42%)
were diabetics, which equals to 34.20% of all diabetics
registered in GP's practices (690), 72 were patients with
TIA/CVI (5.62%), and 244 (19.05%) were coronary heart
disease patients.
All 7 participating GPs were women who hadn’t com-
pleted their residency yet, aged 39±5.49 years, in service
for 13±6 years (median 10 years; range 4–20 years). The
average number of enlisted patients per GP was 1.562±299
(median 1.473; 1.279–1.960), average number of daily
visits 46±10.88 (median 45; 27–60). There was a signifi-
cant difference among them: two of them together pre-
scribed significantly more statins than all the others
(c2=668.0; p<0.001), both in primary (c2=752.9; p<0.001)
and secondary CVD prevention (c2=64; p<0.001).
Discussion
Our study showed interesting ratio of statin prescrip-
tion in PP (64.11%) compared with SP (35.88%). The fact
that in primary CVD prevention statins are most fre-
quently prescribed in population aged 70+ raises con-
cerns. Age groups 40–69 are unfairly neglected in PP of
cardiovascular diseases. GPs have no proactive approach
to identification and treatment of risk factors in those
age groups, thus reducing the total risk of developing
CVD. Since 70+ population seeks medical attention most
often, it is not surprising that this population segment is
most often treated as well. In year 2001, Croatian Minis-
try of Health and Social Welfare launched the National
Plan and Programme for Prevention of Cardiovascular
Diseases. There is also Plan and Programme for Health-
care Measures covered by the Basic Health Insurance22.
However, these programmes have never been implemen-
ted, so the GPs are neither bound by any obligations, nor
encouraged to pursue with the systematic, active identi-
fication and management of CV risk factors in the CVD
primary prevention.
Even more so, do GPs, as the parties contracting with
the CIHI, economize on statin prescriptions? The CIHI
contract obliges them to allocate only limited financial
means for drug prescription purposes; in case of breach-
ing their contract obligations, the CIHI is entitled to fine
them. Out of total financial means CIHI allocated to GPs
in 2005, for covering prescription drugs aimed at CV pre-
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TABLE 1
DISTRIBUTION OF STATIN PRESCRIPTION IN PRIMARY AND
SECONDARY CARDIOVASCULAR (CV) PREVENTION
Patients
Type of CV Prevention N (%)
Primary Secondary
Gender Men 237 (28.83) 176 (38.26)
Women 585 (71.17) 284 (61.74)
Total 822 (100.00) 460 (100.00)
Age <40 23 (2.80) 3 (0.65)
40–49 97 (11.80) 16 (3.48)
50–59 207 (25.18) 67 (14.57)
60–69 205 (24.94) 147 (31.96)
70 290 (35.28) 227 (49.35)
Total 822 (100.00) 460 (100.00)
vention, 62.5% was spent on antihypertensive drugs,
22.6% on statins, and 14.4% on oral antidiabetics23. Is
such statin prescription satisfactory? Should all diabetics
having total cholesterol level >4.5 mmol/L be prescribed
statins, or should it be restricted to those with docu-
mented coronary heart disease – the answer to this ques-
tion is still pending24,25. However, most diabetics, in or-
der to reach the target TC levels of <4.5 mmol/L and
LDL-C levels of <2.5 mmol/L, require statin prescrip-
tion. In the Republic of Croatia the statin prescription
should be increased, but it depends on financial re-
sources of a particular country. For instance, in 2002, Eu-
ropean Union member states spent 15–18% of their
healthcare budget on drugs. Out of total 2003 budget al-
located for drugs, Croatia spent 30% on drugs for preven-
tion and treatment of CV diseases, while Sweden spent
69%, Finland 52% and Great Britain 49%23.
The initial treatment of hyperlipidemia in primary
and secondary prevention is unexceptionally non-phar-
macological one26. Only in case when three-month-last-
ing hypolipemic diet fails to yield satisfactory results,
pharmacotherapy, using statins as the first-choice drugs,
is applied. It is hard to change patterns of deep-rooted
patients’ behaviour, since there is no perception of antici-
pated risk in asymptomatic patients. Patient and GP cre-
ate a joint motivational plan and set the goals to be ac-
complished in the specific time frame, the patient thus
being an active partner in caring for his/her own health.
Lifelong compliance with new patterns of behaviour, and
continuous treatment with prescribed drugs, should turn
into a permanent lifestyle of a risky patient. However,
long-term compliance with general measures is not easy,
only 10% of people succeed in it27. Some insurance com-
panies established in Great Britain, South Africa and
USA, go so far as to cut down health insurance premiums
to those leading a healthy life and respond to screening
visits on a regular basis28. In most patients, target total
and LDL-cholesterol levels can be maintained by combin-
ing non-pharmacological measures and adequately dosed
statins.
Statin administration in the secondary preventions is
justified, even more so, the larger the number of CV risk
factors, the better are the results achieved by statin use,
as it is shown in 4S study, too. It demonstrated that rela-
tive risk reduction attained by simvastatin in diabetics
almost doubled (55%) compared with non-diabetics (32%)6.
Nevertheless, in our study the number of statin-receiv-
ing diabetics was fairly low. The total number of diabetics
registered in our 7 GPs' practices is conforming to the es-
timated data on diabetes prevalence in adult Croatian
population, which is 9.5%29. In his/her everyday practice,
a GP carries out an opportunistic screening of persons at
risk of developing diabetes, although the Programme for
Cardiovascular Disease Prevention in Family Medicine
from 200330, recommends each and every person aged
over 40 to have blood glucose test once in 2 years, and re-
peat it every 5 years if the baseline findings are within
normal levels. Again, there is no possible way of imple-
menting this programme into everyday practice. The sig-
nificant obstacle for implementing preventive activities,
both in majority of European countries and in Croatia, is
an excessive daily workload of FD and the lack of time for
such such activities31. Instead of a systematic proactive
approach to primary prevention in population with CVD
risk factors, prevention activities are non-systematic, in-
dividual, non-integral and sporadic. Preventive, proac-
tive approach is increasingly more often replaced by a re-
active, curative approach (aimed at sheer »fire extinc-
tion«), less beneficial for the patient, and more expensive
for the entire healthcare system.
Significant variations in primary and secondary sta-
tin prescription among the participating GPs cannot be
explained either by differences in their individual char-
acteristics (age, gender, years of service) or by differences
in their practices (degree of computerisation, the number
of beneficiares they care for, number of daily visits), since
they are marginal. The differences in morbidity of popu-
lation enlisted per GP are also negligible. Possible expla-
nation may lie within the fact that none of the 7 GPs in-
cluded in the study have completed their residency yet.
Statin prescription is one of the important quality
care indicators in family medicine32. It is expected to im-
prove after residency completion. Our study should con-
firm or refute this presumption. Since the effect of sim-
vastatin is best documented6, we expected this statin to
be the most frequently prescribed in both primary and
secondary prevention. According to the current state of
knowledge, all statins are similarly effective in long-term
CVD prevention, exhibiting the so-called »class effect«,
which was investigated in both primary and secondary
prevention. Mutual pharmacokinetic differences are only
minimal33–35; therefore, bearing in mind their similar ef-
ficiency, a cheaper drug should be prescribed. The results
of our investigation demonstrated that atorvastatin was
the most frequently prescribed statin in the primary pre-
vention. This could be explained by impact of aggressive
pharmaceutical marketing. Biased medical education spon-
sored by pharmaceutical companies reflects in GPs' pre-
scribing patterns, since there is no independent extra-in-
stitutional education.
Our research showed that a 10 mg statin daily dose
was most frequently prescribed in PP, while in SP it was
a 20 mg dose. According to the GOALLS study, the ma-
jority of patients in secondary prevention treatment re-
quire 20 mg simvastatin to reach target total cholesterol
level, which is in accordance with our results, while 14%
of the patients need an 80 mg simvastatin dose36. In our
study, 80 mg daily dose was administered to only 3.8% of
the patients. The randomised, controlled IDEAL study
demonstrated that higher statin doses are equally safe,
because the frequency of adverse side effects in patients
treated with 80 mg atorvastatin in secondary prevention
was not superior to that with 20 mg simvastatin37. The
fear of adverse events when treating hypercholesterol-
emia with higher doses (miopathy, muscle weakness) is
utterly unjustified. The incidence of these side effects is
approximately 1–5%, while rhabdomyolysis, the most se-
vere adverse side effect, is extremely rare38.
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GPs participating in our study did not follow CIHI
guidelines for prescribing statins in primary prevention.
They prescribed them at lower average total cholesterol
levels, while in secondary prevention statin prescription
met the prescribing guidelines regarding both indicati-
ons and required total cholesterol threshold levels. How-
ever, the question remains whether CIHI regulations are
exclusively powered by administrative and financial mo-
tives, or based on the recommendations and guidelines of
professional societies. Croatian Society of Cardiology and
Croatian Society of Hypertension39,40 adopted ESC-ESH
guidelines, which adjust statin treatment to the total ab-
solute 10-year risk of a fatal CV event assessed by the
SCORE tables applicable for primary prevention. But
CIHI guidelines are focused solely on total cholesterol
level concentration as an individual, isolated CVD risk
factor, which is an unreasonably simplified approach.
The total CVD risk is crucial for the CV risk assessment,
since it is always higher than the simple sum of individ-
ual factors because of their mutual interactions. For ex-
ample total CVD risk can be high due to patient’s age,
gender, smoking status, and systolic blood pressure, de-
spite TC concentration <7mmol/L. By rigid compliance
with CIHI guidelines in PP is strict, a GP is not allowed
to prescribe statin to such a patient, while at the same
time, treatment is strongly and clearly recommended by
professional societies guidelines39,40. In our study, GPs
prescribed statins in the best interest of their patients,
violating their contracting obligations to the CIHI and
risking to be fined. Such a situation is absurd and im-
poses the need for harmonisation of guidelines proposed
by professional societies and those issued by CIHI, as
well as greater CIHI financial resources for prescription
drugs.
Nowadays, it is hard to find systematic medical educa-
tion independent of pharmaceutical industry. There is a
large gap between CVD prevention guidelines provided
by professional societies and their implementation. Be-
tter and independent GP education could result in wider
implementation of the existing CVD prevention pro-
grammes and significantly lower CVD morbidity and
mortality currently present in the Republic of Croatia.
The fact that statins are most frequently prescribed in
patients aged 70+ is concearning and reveals lack of pre-
ventive proactive CVD approach in younger age groups.
This study is limited by GP's sampling, which is far
from random or representative for a Croatian GP. But its
advantage is that it is homogenous and of an independ-
ent origin. This research may be considered as a pilot in-
vestigation, which should enhance further study of statin
prescription patterns and GP's activities in primary and
secondary CVD prevention.
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PROPISIVANJE STATINA OD STRANE OBITELJSKIH LIJE^NIKA U HRVATSKOJ – IZOSTANAK
SUSTAVNOG PROAKTIVNOG PRISTUPA PREVENCIJI KARDIOVASKULARNIH BOLESTI
S A @ E T A K
Cilj je bio istra`iti propisivanje statina od strane obiteljskih lije~nika (LOM) u primarnoj (PP) i sekundarnoj (SP)
prevenciji kardiovaskularnih bolesti. Zabilje`eni su socio-demografski podatci o bolesnicima, koncentracija ukupnog i
LDL-kolesterola koje su bile indikacija za za propisivanj statina, kao i podatci o lije~nicima. Statini su propisani u 11,2%
svih bolesnika u skrbi (64,11% PP, 35,88% SP), naj~e{}e `ivotne dobi 70+. U primarnoj prevenciji indikacija za propi-
sivanje bila je koncentracija ukupnog kolesterola 6,2±1,09 mmol/L, LDL-kolesterola 3,6 mmol/L, a u SP 5,4±1,26; 2,7
mmol/L. Najpropisivaniji statin u PP bio je atorvastatin u dozi 10 mg (49,28%), a u SP simvastatin (48,36%) u dozi 20
mg. Sve LOM bsu `ene, dobi 39±5,49 godina, radnog sta`a 13±6 godina, s prosje~nim brojem pacijenata u skrbi 1562±299.
Statisti~ki zna~ajna razlika me|u njima utvr|ena je u preskripciji statina u PP (c2=752,9; p<0,001) i SP (c2=64, p>0,001).
Preskripcija statina u PP rezultat je utjecaja farmaceutskih tvrtki i nedostatka od njih neovisne kontinuirane edukacije
LOM. Naj~e{}e propisivanje statina u dobi 70+ (35,28% in PP, 49,35% SP) ukazuje na nedostatak proaktivnog pristupa
u prevenciji KV bolesti mla|im dobnim skupinama.
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